ライフサイエンスコーパス: myxoid

1 es of CS (8 extraskeletal myxoid, 4 skeletal myxoid, 4 mesenchymal, and 30 other) for the EWS/CHN gen

2 We studied 46 cases of CS (8 extraskeletal myxoid, 4 skeletal myxoid, 4 mesenchymal, and 30 other)

3 iated, 143 (18%) dedifferentiated, 144 (18%) myxoid, 81 (10%) round cell, and 64 (8%) pleomorphic his

4 pendent prognostic factor in the spectrum of myxoid and round-cell liposarcomas has not been examined

5 Forty-seven cases of myxoid and round-cell liposarcomas were examined.

6 expression predicts the clinical behavior of myxoid and round-cell liposarcomas, even in neoplasms wi

7 65 (37%) with dedifferentiated, 9 (5%) with myxoid, and 4 (2%) with round cell morphology.

8 Areas of myxoid change showed similar but less pronounced alterat

9 Extensive areas of myxoid change were found in all aortic valves.

10 The pathogenesis of myxoid chondrosarcoma (CS) is poorly understood.

11 studies have established that extraskeletal myxoid chondrosarcoma is a unique entity defined by the

12 locations (eg, cemento-ossifying fibroma and myxoid chondrosarcoma) and the association of establishe

13 uperfamily located at 9q22-31, in a skeletal myxoid chondrosarcoma.

14 A proportion of extraskeletal myxoid chondrosarcomas (EMC) have been shown to have a c

15 r genetic findings, except for extraskeletal myxoid chondrosarcomas.

16 etic changes are diagnostic of extraskeletal myxoid chondrosarcomas.

17 (32%) had unusual histologies (pleomorphic, myxoid, clear cell, and signet ring cell).

18 = 0.01); 83.3% of those with a non-fatty/non-myxoid component greater than 50% were high grade (p = 0

19 0.01); 83.3% of those with a non-fatty / non-myxoid component greater than 50% were high grade (p=0.0

20 All the tumors with a myxoid component of less than 25% were high grade (p = 0

21 All the tumors with a myxoid component of less than 25% were high grade (p=0.0

22 y component, myxoid component, non-fatty/non-myxoid component, apparent diffusion coefficient (ADC),

23 component, myxoid component, non-fatty / non-myxoid component, apparent diffusion coefficient (ADC),

24 ures (size, depth, borders, fatty component, myxoid component, non-fatty / non-myxoid component, appa

25 ures (size, depth, borders, fatty component, myxoid component, non-fatty/non-myxoid component, appare

26 gs in the latter cases suggest that skeletal myxoid CS is pathogenetically distinct from its extraske

27 Notably, 2 cases of extraskeletal myxoid CS showed neither an EWS/CHN fusion transcript no

28 Extraskeletal myxoid CS thus represents yet another sarcoma type conta

29 g genetic heterogeneity within extraskeletal myxoid CS.

30 ognized in CS, specifically in extraskeletal myxoid CS.

31 ed in only a limited number of extraskeletal myxoid CSs and its presence in other types of CS has not

32 e fusion was present in 6 of 8 extraskeletal myxoid CSs and was not detected in any of the remaining

33 he remaining cases, including the 4 skeletal myxoid CSs.

34 nitially formed small tumors later underwent myxoid degeneration and completely regressed.

35 ough numerous articles on MVP (myxomatous or myxoid degeneration, billowing or floppy mitral valve) h

36 is a characteristic constituent of the loose myxoid ECM in human restenotic arteries and of the neoin

37 The loose myxoid ECM typical of human restenotic arteries demonstr

38 imaging appearances that probably represent myxoid fibroadenomas or ductal adenomas.

39 s in six patients and complex cystic masses (myxoid fibroadenomas) in one patient.

40 There were 28 patients with conjunctival myxoid lesions diagnosed as myxoma (16/28), conjunctival

41 en neoplastic conjunctival myxomas and other myxoid lesions, underscoring the importance of morpholog

42 relapsed, or metastatic synovial sarcoma or myxoid liposarcoma (any grade) were randomly assigned to

43 in all STS histologies except for high-grade myxoid liposarcoma (HG-MLPS) where S and HT appeared to

44 llowing five histologic subtypes: high-grade myxoid liposarcoma (HG-MLPS); leiomyosarcoma (LMS), syno

45 he FUS::DDIT3 fusion oncoprotein hallmark to myxoid liposarcoma (MLPS) inhibits BAF complex-mediated

46 y reviewed diagnosis of localized resectable myxoid liposarcoma arising from an extremity or the trun

47 rcoma, leiomyosarcoma, dedifferentiated, and myxoid liposarcoma cell lines were used for in vitro stu

48 STS cells, and restored drug sensitivity in myxoid liposarcoma cells resistant to trabectedin.

49 Myxoid liposarcoma is characterized by a pathognomonic c

50 Myxoid liposarcoma is classified in the group of sarcoma

51 However, myxoid liposarcoma is not a homogeneous entity, because

52 However, myxoid liposarcoma is not a homogeneous entity, because

53 c, biopsy-proven and translocation-confirmed myxoid liposarcoma of the extremity or trunk who were en

54 he observed clinical radiosensitivity of the myxoid liposarcoma subtype might offer the possibility t

55 s of formalin-fixed, paraffin-embedded human myxoid liposarcoma tissues, we demonstrate an 80% reduct

56 tion was stratified by histological subtype (myxoid liposarcoma vs others).

57 ed clinical trial including 46 patients with myxoid liposarcoma was conducted in 4 centers in Spain,

58 ors, and one each of infantile fibrosarcoma, myxoid liposarcoma, cellular congenital mesoblastic neph

59 roposed as a dose-fractionation approach for myxoid liposarcoma, given that phase 3 trials are logist

60 nderlies sensitivity to radiation therapy in myxoid liposarcoma.

61 b alone in patients with synovial sarcoma or myxoid liposarcoma.

62 a level comparable to that observed in human myxoid liposarcoma.

63 uch as uveal melanoma, synovial sarcoma, and myxoid liposarcoma.

64 , including a probably causal insertion in a myxoid liposarcoma.

65 se Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas (DOREMY) trial is a prospective, sin

66 ferentiated/dedifferentiated/pleomorphic and myxoid liposarcomas (MLS).

67 differentiating between high- and low-grade myxoid liposarcomas and can help in clinical decision ma

68 pressed in the neoplastic component of human myxoid liposarcomas and increases the tumorigenicity of

69 magnetic resonance imaging (MRI) features of myxoid liposarcomas and to determine whether the MRI fea

70 magnetic resonance imaging (MRI) features of myxoid liposarcomas and to determine whether the MRI fea

71 ombination of trabectedin and RT in treating myxoid liposarcomas appears worth exploring.

72 Of the 23 myxoid liposarcomas that contained no fat, 16 (69.6%) we

73 Of the 23 myxoid liposarcomas that contained no fat, 16 (69.6%) we

74 also explains the remarkable sensitivity of myxoid liposarcomas to radiation therapy.

75 We studied 36 patients with myxoid liposarcomas treated at our center between 2010 a

76 We studied 36 patients with myxoid liposarcomas treated at our centre between 2010 a

77 In our series, patients with myxoid liposarcomas were mainly young adults (median age

78 Synovial sarcomas, round-cell/myxoid liposarcomas, clear-cell sarcomas and gastrointes

79 oncoprotein, found in the majority of human myxoid liposarcomas, consists of a fusion between the tr

80 ar, a subset of Ewing's family of tumors and myxoid liposarcomas, which lack one of the characteristi

81 ET) protein-cooperated FUS-DDIT3 function in myxoid LPS and a BET protein-dependent core transcriptio

82 ogical function and protein structure of the myxoid matrix in optic gliomas to identify novel therape

83 The myxoid matrix is composed predominantly of the proteogly

84 The patients with abundant myxoid matrix lesions (14/28, 50%) were younger (mean 49

85 68] years) than those with scant-to-moderate myxoid matrix lesions (14/28, mean 61 [range 18-82] year

86 Abundant myxoid matrix lesions more likely contained predominantl

87 ted adipocytes, primitive mesenchymal cells, myxoid matrix, and fibrous trabeculae.

88 erent stages of maturation within a variably myxoid matrix, and they contain clonal rearrangements of

89 oma, a subtype of optic glioma with abundant myxoid matrix, is characterized by the presence of endot

90 Optic gliomas contain various amounts of myxoid matrix, which can represent most of the tumor mas

91 luronan and proteoglycan link protein 1 rich myxoid matrix, which is in direct contact with circulati

92 presence of endothelium-free channels in the myxoid matrix.

93 optic gliomas, which varied in the amount of myxoid matrix.

94 clusion and multinucleated cells in a partly myxoid matrix.

95 mbled the loose-connective-tissue-containing myxoid region typical of restenotic lesions.

96 tastatic or unresectable synovial sarcoma or myxoid round cell liposarcoma (confirmed by cytogenetics

97 Myxoid round cell liposarcoma (MRCLS) is a common liposa

98 ically confirmed synovial sarcoma (n=44) and myxoid round cell liposarcoma (n=8) were enrolled and re

99 d 25% (two of eight; 3-65) for patients with myxoid round cell liposarcoma.

100 E-A4-expressing advanced synovial sarcoma or myxoid round cell liposarcoma.

101 of well-differentiated liposarcomas, >90% of myxoid round cell liposarcomas, and >70% of pleomorphic

102 DSS were smaller size (HR = 0.7, P = 0.01), myxoid/round cell histologic subtype (HR = 0.3, P = 0.03

103 cinoma 1 (NY-ESO-1) is a promising target in myxoid/round cell liposarcoma (MRCLS).

104 nd induces apoptosis in dedifferentiated and myxoid/round cell liposarcoma cell lines, but not in eit

105 a) well-differentiated/dedifferentiated, (b) myxoid/round cell, and (c) pleomorphic, based on morphol

106 ith advanced or metastatic dedifferentiated, myxoid/round cell, or pleomorphic LPS incurable by surge

107 pleomorphic liposarcomas) and PIK3CA (18% of myxoid/round-cell liposarcomas, or MRCs).

108 hildren that is characterized by a primitive myxoid stroma with cystically dilated bile ducts.

109 agen and elastic fibers) with focal areas of myxoid stroma, with or without coverage by endothelial c

110 Myxoid tissue containing extracellular matrix (ECM) enri

111 The stroma seemed to be myxoid to collagenous.

112 ;22)(q22-31;q11-12) has been observed in the myxoid variant of human chondrosarcoma.

113 ate-like channels, which we termed primitive myxoid vascularization.